The Lancet infectious diseases
-
Comment Letter
Stepped-wedge trial design to evaluate Ebola treatments.
-
ENCORE1 Study Group. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Lancet Infect Dis 2015; published online April 13. http://dx.doi.org/10.1016/S1473- 3099(15)70060-5—In this Article, the numbers of patients in the 96-week adverse events analysis were incorrect.